GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » Equity-to-Asset

Vidac Pharma Holding (STU:T9G) Equity-to-Asset : -10.43 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vidac Pharma Holding's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €-1.14 Mil. Vidac Pharma Holding's Total Assets for the quarter that ended in Jun. 2024 was €0.11 Mil.

The historical rank and industry rank for Vidac Pharma Holding's Equity-to-Asset or its related term are showing as below:

STU:T9G' s Equity-to-Asset Range Over the Past 10 Years
Min: -15.93   Med: -10.43   Max: -1.28
Current: -10.43

During the past 3 years, the highest Equity to Asset Ratio of Vidac Pharma Holding was -1.28. The lowest was -15.93. And the median was -10.43.

STU:T9G's Equity-to-Asset is ranked worse than
97.74% of 1507 companies
in the Biotechnology industry
Industry Median: 0.67 vs STU:T9G: -10.43

Vidac Pharma Holding Equity-to-Asset Historical Data

The historical data trend for Vidac Pharma Holding's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding Equity-to-Asset Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23
Equity-to-Asset
-0.65 -15.93 -6.36

Vidac Pharma Holding Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset -1.28 -15.93 -15.39 -6.36 -10.43

Competitive Comparison of Vidac Pharma Holding's Equity-to-Asset

For the Biotechnology subindustry, Vidac Pharma Holding's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vidac Pharma Holding's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's Equity-to-Asset falls into.



Vidac Pharma Holding Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Vidac Pharma Holding's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-0.878/0.138
=

Vidac Pharma Holding's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=-1.137/0.109
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vidac Pharma Holding  (STU:T9G) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Vidac Pharma Holding Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vidac Pharma Holding Business Description

Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines